NCT01698294 is a NA clinical trial of Clinical Observation in No Evidence of Disease, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT01698294?

NCT01698294 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT01698294?

Interventions in NCT01698294: Clinical Observation, Flaxseed, Laboratory Biomarker Analysis, Questionnaire Administration.

What condition does NCT01698294 study?

NCT01698294 studies No Evidence of Disease.

Is NCT01698294 still recruiting?

NCT01698294 is currently completed. Last updated 9 May 2022.

Last reviewed 2022-05-09 · How we verify

NCT01698294

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers in Post-Menopausal Women Receiving Flaxseed

Completed NA Last updated 9 May 2022

What this trial tests

NA trial testing Clinical Observation in No Evidence of Disease in 258 participants. Completed in 8 June 2017.

Timeline

14 December 2012

Primary endpoint
8 June 2017

8 June 2017

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	258
Start date	14 December 2012
Primary completion	8 June 2017
Estimated completion	8 June 2017
Sites	1 location across United States

Drugs / interventions tested

Clinical Observation
Flaxseed — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Questionnaire Administration

Conditions studied

No Evidence of Disease — all drugs for No Evidence of Disease →

Sponsor

Roswell Park Cancer Institute

Who can join

Adults 45 to 80, female only, with No Evidence of Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized clinical trial studies biomarkers in post-menopausal women receiving flaxseed. Studying samples of blood, urine, and feces in the laboratory from participants receiving flaxseed may help doctors understand the effects of flaxseed on biomarkers.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Enterolignan Production in a Flaxseed Intervention Study in Postmenopausal US Women of African Ancestry and European Ancestry.
McCann SE, Hullar MAJ, Tritchler DL, Cortes-Gomez E, et al · · 2021 · cited 19× · PMID 33809130 · DOI 10.3390/nu13030919
Genetic Variation in Steroid and Xenobiotic Metabolizing Pathways and Enterolactone Excretion Before and After Flaxseed Intervention in African American and European American Women.
Chang H, Yao S, Tritchler D, Hullar MA, et al · · 2019 · cited 11× · PMID 30709839 · DOI 10.1158/1055-9965.epi-18-0826
Recruitment and Retention of Healthy, Postmenopausal Women of African and European Ancestry: Results from a Dietary Intervention with Repeated Biospecimen Collections.
McCann SE, Rodriguez EM, Erwin D, Yao S, et al · · 2022 · cited 1× · PMID 35261959 · DOI 10.1093/cdn/nzac012

Verify or expand the search:

Other trials of Clinical Observation

Trials testing the same drug.

NCT06200103 — Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer · Phase 2 · recruiting
NCT05995925 — Observational Study for Perioperative Care of Patients Requiring ICU (OPICU) · unknown
NCT05375799 — Clinical and Electronic Record for Patients With COVID-19 Treated With the Assisted Breathing Helmet - ELMO in Ceará · unknown
NCT04519879 — White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA · Phase 2 · active not recruiting
NCT04649827 — A Clinical Trial for Hospitalized Patients With COVID-19 in Ceará: ResCOVID Study · unknown

Other recruiting trials for No Evidence of Disease

Currently open trials in the same condition.

NCT01230346 — Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer · NA · active not recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01698294 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 9 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01698294.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing